placebo. As well AAP had a statistically significant higher risk of asthenia, fatigue, pain, cardiac, gastrointestinal and metabolism disorders when compared to placebo. Real life data from Eudra Vigilance database reports: ear, eye, endocrine, immune, psychiatric, renal, respiratory and skin disorders which are not reported in the registry study (Table1). Number of adverse events comparing the two frame times has increased in relation to the widespread use of both drugs and particularly ENZ in the last three years. The distribution of different AEs has not significantly changed, except the reduction in the last three years of cardiac and Ear/labyrinth events in patients treated with AAP and blood/lymphatic and hepatobiliary disorders in patients treated with ENZ (Table 1) .
CONCLUSIONS: Real life data are not consistent with registry study data in the evaluation of AAP and ENZ complications particularly regarding psychiatric, respiratory and skin disorder. Number of AEs has increased in the past three years in relation to the widespread use of these new drugs. Change over time in some adverse events could be related to a better confidence in managing these new drugs and/or to a better patients 'selection Source of Funding: None
MP34-15
TREATMENT OUTCOME OF DOSE REDUCTION OF ENZALUTAMIDE AGAINST CRPC Naokazu Ibuki*, Teruo Inamoto, Atsushi Ichihashi, Hirofumi Uehara, Kazumasa Komura, Hajime Hirano, Hayahito Nomi, Haruhito Azuma, Osaka, Japan INTRODUCTION AND OBJECTIVES: Enzalutamide has a good therapeutic effect on CRPC and is widely administered as an important treatment option. But, Enzalutamide has various adverse reactions, especially in cases where fatigue is observed, and Enzalutamide is administered in a reduced amount in the actual clinical setting. In this study, we aim to examine side effects and therapeutic effects of administration of Enzalutamide in normal dose and reduced dose.
METHODS: From February 2014 to May 2017, Enzalutamide was normally administered in 113 cases, and in 42 cases it was administered in a dose-reduced manner. Patient background, side effects and treatment effect were compared. The patient background and treatment outcome were evaluated. All data was analyzed using SPSS ver24.
RESULTS: The median age, dosing period of Enzalutamide, and biopsy Gleason score are examples in which all Enzalutamide was administered, examples in which dosage was reduced, 74.1 years old, 73.4 years old, 7 months, 8 months, 8.3, 8.5, And no difference was found between the two groups. PS before administration was in the total dose administration group and 105 cases and 8 cases with PS 0 to 1, 2 to 3, in the group administered with reduced dose, 0 to 1, 2 to 3 were 36 cases, 6 cases. In the case of administration with reduced dose, the percentage of patients with poor PS was high. The median PSA at diagnosis of prostate cancer and PSA at diagnosis of CRPC was 94.0, 8.03 in the case of the total administration and 81.4, 5.62 in the case of reduced dose administration. The PSA value was low in the case of reduced dose administration. There were no differences in side effects in 31 cases (27.4%) in 113 patients in the whole dose group and in 10 cases (23.8%) in 42 subjects in reduced dose group. During the study period, 69 patients continued in the total dose group and 44 patients with withdrawal were 44 (PSA elevation 40 cases, side effects 2 cases, 2 deaths), 32 cases continued in the reduced dose group, 10 cases were withdrawn (PSA increased 8 cases, 2 cases of side effects), and interruption due to elevated PSA was abundant in the whole dose group and there was no difference in discontinuation due to side effects. And, there was no significant difference in PSA progression free survival between the two groups. CONCLUSIONS: No difference was observed between the two groups due to the occurrence rate of side effects and the therapeutic effect in comparison between the group administered in total amount of Enzalutamide and the group administered in reduced dose. For elderly people and patients with poor PS, reduced dose administration could be considered an option.
Source of Funding: none

MP34-16 A NOVEL ANDROGEN RECEPTOR (AR) ANTAGONIST JJ-450 INHIBITS ENZALUTAMIDE-RESISTANT MUTANT AR F876L
Zeyu Wu*, Zhenyu Yang, Laura Pascal, Keita Takubo, Joel Nelson, Peter Wipf, Zhou Wang, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is the most common cancer and second leading cause of cancer-related deaths in US males. PCa patients treated with androgen deprivation therapy (ADT) will inevitably develop castration-resistant prostate cancer (CRPC). Second generation anti-androgens such as enzalutamide were developed for treating CRPC. However, CRPC can develop resistance to enzalutamide because of androgen receptor (AR) point mutations, AR overexpression, constitutively active AR splice variants, and elevated intratumoral androgen synthesis. For example, AR F876L was reported to be stimulated, instead of inhibited, by enzalutamide, contributing to enzalutamide resistance. New approaches to treat enzalutamide-resistant CRPC are urgently needed. We have recently developed JJ-450 as a novel AR antagonist with potential to treat enzalutamide-resistant CRPC. Objectives: To determine if JJ-450 is capable of inhibiting the function of AR F876L.
METHODS: We employed prostate-specific antigen (PSA) enhancer/promoter-based luciferase assay to determine AR transcriptional activity, quantitative real-time polymerase chain reaction (qPCR) assay and western blot to detect expression of AR target genes at mRNA and protein level, fluorescence microscopy to show AR subcellular localization, and 5-bromo-2'-deoxyuridine (BrdU) assay to measure prostate cancer cell proliferation.
RESULTS: As expected, enzalutamide inhibited wild-type (wt) AR but not AR F876L transcriptional activity in luciferase assay. In contrast, JJ-450 inhibited both wt-AR and AR F876L transcriptional activity. Also, enzalutamide retarded androgen-induced nuclear import of GFP-AR, but not GFP-AR F876L, whereas JJ-450 retarded nuclear import of both GFP-AR and GFP-AR F876L. To further evaluate JJ-450 inhibition of AR F876L, we stably transfected C4-2 cells with GFP-AR and GFP-AR F876L separately. Enzalutamide inhibited endogenous AR-target gene expression in C4-2-GFP-AR, but not C4-2-GFP-AR F876L subline, whereas JJ-450 inhibited AR-target gene expression in both C4-2 sublines. More importantly, enzalutamide inhibited proliferation of C4-2-GFP-AR, but not the C4-2-GFP-AR F876L subline, whereas JJ-450 inhibited proliferation of both C4-2 sublines.
CONCLUSIONS: JJ-450 can inhibit enzalutamide-resistant ARF876L in prostate cancer cells.
